

Index

Page numbers in *italic* refer to figures; those in **bold** refer to tables
Numbers are filed as spelled out

- ABL1* gene, 86, 87
Aconitum, herbal cancer treatment, 23
 acoustic neuroma, 143
 actinomycin D, 156
 activation immunotherapies, 174–175
 acute lymphoblastic leukaemia (ALL)
 chemotherapy, 156
 chromosome translocation, 86, 87
 combination chemotherapy, 157
 gene therapy, 177–178
 acute myeloid leukaemia (AML)
 alpha particle therapy, 190
 combination chemotherapy, 157
 metabolic targets for anti-cancer
 drugs, 164
 acute promyelocytic leukaemia
 (APL), 157
 acute radiation syndrome, 140
 adenoviruses, 164–165
 ADH (alcohol dehydrogenase), 106
 adjuvant chemotherapy, 155
 adoptive cell therapy, 177, 179
 adult T cell leukaemia (ATL), 98
 Africa, epidemiology of cancer, 38,
 46–47
 African traditional diets, and colon
 cancer, 113–114
 AG-221 (enasidenib), 164
 age standardization, incidence and
 mortality, 36–38
 ageing, and cancer risk, 5, 16,
 76
 alcohol dehydrogenase (ADH),
 106
 alcohol use, 105–106, 146
 ALL see acute lymphoblastic leukaemias
 Allison, James, 175, 211–214
 alpha particles, 135, 190
 American Institute for Cancer Research,
 111, 145
 AMG 510 molecule, 192–193
 amino acids, 4, 54–55; see also proteins
 aminopterin, 156
 AML see acute myeloid leukaemia
AML1 gene, 87
 Ancient China, 22–23
 Ancient Egypt, 19–20
 Ancient Greece, 20–21
 angiogenesis, 2
 nanorobotics, 189

218 INDEX

- angiogenesis (cont.)
 targets for anti-cancer drugs, 159, 165–166
- animal cancers, 20, 21
- antibiotics
 resistance to, 147–148
 role in causation of cancer, 123–124
 role in chemotherapy, 123, 156
- antibodies, monoclonal, 162, **163**
- antioxidants, 111, 128–129
- anti-proliferents, 156, 159
- APL (acute promyelocytic leukaemia), 157
- apoptosis, 57, 159, 164–165
- Arber, Werner, 58, 211–214
- aromatase inhibitors, 158
- artificial intelligence, definition, 100
- asbestos, 133
- Asia, epidemiology of cancer, 46
- ataxia telangiectasia (AT), 94–95
- ATL (adult T cell leukaemia), 98
- atoms, 49
- Australia, epidemiology of cancer, 36, 38
- Avastin, 165–166
- Aykut, Berk, 126–128
- azacitidine (AZA), 186, 187
- B cells, 162
- Babeş, Aurel, 148
- Bacillus Calmette–Guerin (BCG)
 vaccine, 171
- bacterial infections
 antibiotic resistance, 147–148
 inhibitory effects on cancers, 175
- Bacteroides thetaiotaomicron*, 112
- Bacteroidetes*, 122
- Baltimore, David, 59, 211–214
- Bardeen, John, 60
- Barrett's oesophagus, 182–184
- base editing, 178; *see also* DNA
- BCG vaccine, 171
- BCR gene, 86, 87
- Beatson, George Thomas, 27–28
- Becquerel, Henri, 136
- benign tumours, 6–8
- Bennett, John Hughes, 30
- BET (bromodomain) inhibitors, 187
- beta particles, 135
- Billroth, Christian Albert Theodor, 26–27
- biochemistry, 33
- biomarkers, tumour, 149, 154, 168–169
- biopsy, 153
 breath, 182
 liquid, 181–182
- birthmarks, 8–9
- Bishop, Michael, 80, 211–214
- bladder cancer, 171
- Blaser, Martin, 124
- blindness, BRILLIANCE trial, 180
- blood–barrier, 168–169
- Boveri, Theodor, 31–33
- bowel cancer *see* colorectal cancer
- brachytherapy, 153
- Bradley, Allan, 92
- BRAF* gene, 160–161
- BRAF* kinase inhibitors, **160**
- brain tumours, exosomes, 168–169; *see also* glioblastoma multiforme; glioma
- brassicas, dietary, 110, 112
- BRCA1/BRCA2* genes, 4–5
 breast cancer screening, 151
 single-nucleotide polymorphisms, 96
 synthetic lethality, 190–192, 191
 vemurafenib blockade, 192
- breast cancer, 4–5
 alcohol use, 106
 causation, 110
 circadian rhythms, 144
 cortisol, 144
 epidemiology, 36, 39, 40
 gene amplification, 89

- historical perspectives, 24–25, 27–28
- machine learning approach, 198
- metastasis, 169–170
- mutational signatures, 196–197
- screening for, 149–151
- selective oestrogen receptor modulators, 158–160
- single-nucleotide polymorphisms, 96
- smoking, 132
- tumour microenvironment, 197
- breath biopsy, 182
- Brenner, Sydney, 52, 56–57, 211–214
- BRILLIANCE trial, gene therapy, 180
- British Medical Journal*, 150
- Broca, Paul, 4
- Burkitt's lymphoma, 88, 98

- cachexia, 13
- Caenorhabditis elegans* model organism, 56–57
- caesium, radioactivity, 139–140
- Cairns, John, 52
- calcium, role in cancer, 113
- Caldas, Carlos, 196
- Camellia* (tea), antioxidants, 128–129
- Campbell, Peter, 195
- cancer antigen 125 (CA125)
 - biomarker, 149
- cancer, general information, 1–2, 16–18, 47, 200–201
 - bacterial resistance to antibiotics analogy, 147–148
 - best practice to avoid cancer, 116–118, 145–146
 - biomarkers, 149, 154, 168–169
 - causation, 3–6
 - classification of types, 10–11, 101–102, 203
 - common misunderstandings, 202–203
 - definition and nature of, 2, 66, 202
 - diagnosis/staging/grading, 151–154
 - imaging, 151–154, 152
 - lethality/mortality of, 13
 - numbers, see epidemiology of cancer
 - paradox of, 2
 - screening, 148–151
 - sensitivity and specificity in detection, 148
 - see also causatory factors; genetics of cancer; treating cancer
- Cancer Genome Atlas (TCGA), 98
- CancerLocator program, 185
- Candida* spp., human microbiome, 126
- Canon, Jude, 192–193
- Caravagna, Giulio, 100
- carcinomas, 10
- CAR-T cell therapy, 177–178, 180–181
- case-control studies, role of diet in cancer, **109**
- caspase inhibitors, 164
- causatory factors in cancer, 3–6
 - alcohol use, 105–106
 - DNA instability, 103–104
 - epidemiology of cancer, 46–47
 - genes controlling cell signalling/cell division, 70–71
 - hereditary and environmental causes, 103
 - infection, 134–135
 - lifestyle factors, 47
 - Nurses' Health Study, 109–110
 - replicative mutations, 104, 105
 - stress, 144–145
 - UK epidemiology, 40–41, 42
 - uncontrollable causes, 134, 145–146
 - USA epidemiology, 42
 - see also diet; electromagnetic radiation; obesity; smoking
- CDK see cyclin-dependent kinase inhibitors
- CD19 protein, 177–178
- CD20 protein, 162

220 INDEX

- cell biology, 64–66, 69
 historical perspectives, 29–34
 membranes, 65–66
- cell cycle/cell division, 71–72, 72
 cell signalling, 68
 regulatory control, 72–75, 73
- cellphones, high-frequency magnetic fields, 143
- cell signalling, 66–69, 68
 DNA mutations building faulty proteins, 82–84, 84
 drugs targeting, 70, 160–161, 172, 172
 effects of alcohol use, 106
 effects of obesity, 120–121
 epidermal growth factor receptor, 84–86, 85
 metastasis, 167
 personalized medicine, 193, 194
 RAS gene, 83–84
 role of microbiome, 125
 role of mycobiome, 127
 steroid hormones, 69–70
 synthetic lethality, 190–192
- cells behaving badly, 2, 66
- cellular bookmarking, 167
- central dogma of molecular biology, 53
- CEP290* gene, 180
- cervical cancer
 historical perspectives, 24–25
 human papillomaviruses, 97
 screening, 149
- Channing Der, 81
- Chase, Martha, 49
- checkpoint inhibitors, 175–177, 176
 inhibitory effects of bacterial infection, 175
 T-cell inhibition, 175–177, 176
- The Chemist's English* (Schoenfeld), 49
- chemotherapy, 154–155, 156
 angiogenesis targets, 159, 165–166
 anti-proliferent targets, 156, 159
- apoptosis targets, 159, 164–165
- bacterial resistance to antibiotics
 analogy, 147–148
- classes of targets for anti-cancer drugs, 159
- combination chemotherapy, 157
- drug nomenclature, **160**
- drug resistance, 147–148, 161, 162
- exosomes as targets, 169–170
- historical perspectives, 28–29, 155–157
- immune system role, 172–173
- kinase inhibitors, 161–162
- metabolic targets, 159, 163–164
- metastasis targets, 159, 166–170
- monoclonal antibodies, 162, **163**
- oncogenic viruses as targets, 159, 170
- oncoproteins, 159, 160–161
- role of antibiotics, 123, 156
- selective oestrogen receptor modulators, 158–160
- tumour microenvironment, 159, 172, 172
- tumour/-tissue-agnostic drugs, 159, 171
- vaccines, 170, 171
- Chernobyl power plant accident, radiation, 139–140
- chess, Deep Blue IBM computer, 100
- childhood cancers, 9, 16, 142
- chimeric antigen receptors (CARs), 177–178, 180–181
- chimney sweeps, scrotal cancer, 25–26
- China
 epidemiology of cancer, 46
 historical perspectives, 22–23
- chlorambucil, 156
- choriocarcinoma, 157
- chromatin, 184–185
- chromosomes, 49–50
 rearrangements in cancer cells, 32

- translocation, 86
- see also genetics of cancer
- chromothripsis, 93–95, 99
- chronic infection, cancers arising from, 134–135
- chronic myeloid leukaemia (CML), 86, 162
- cigarette smoking see smoking
- circadian rhythms
 - role in breast cancer, 144
 - role of microbiome, 125–126
- classification of cancer, 10–11
 - common misunderstandings, 203
 - genetic approaches, 101–102
- Clevers, Hans, 122–123
- click chemistry, 189
- Clinton, Bill (US President), 60
- clonal architecture, 87
- cloning vectors, 59
- CML see chronic myeloid leukaemia
- Cochrane Collaboration, 117–118, 150
- coding, protein synthesis, 54–55
- coffee, role in cancer, 128–129
- cohort studies, role of diet in cancer, **109**
- Coley, William, 175
- Collins, Francis, 61–62
- colon cancer see colorectal cancer
- colonoscopy, 149
- colorectal cancer
 - causation, 110
 - chemotherapy, 157
 - epidemiology, 36, 39–40
 - MYC* gene, 88–89
 - role of diet, 111–112, 113–114
 - role of *E. coli*, 122–123
 - screening, 149
- combination chemotherapy, 157
- The Common Thread* (Sulston and Ferry), 60
- complement system, 127
- computed tomography (CT), 136–137, 149, 151–154
- Cormack, Allan McLeod, 137, 211–214
- corticosteroids, 69–70, 158–160
- cortisol, role in breast cancer, 144
- counting cancer, see epidemiology of cancer
- coxcomb plots, breast cancer mutational signatures, 196
- Crick, Francis, 50, 51, 53, 211–214
- Crick, Odile, 57
- CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system, gene therapy, 178–181
- CTLA-4 protein, T-cell inhibition, 175–177
- Curie, Pierre and Marie, 60, 136, 211–214
- CyberKnife System, 155
- cyclin-dependent kinase (CDK) inhibitors, 74, 157, **160**
- cyclophosphamide, 156
- cytoplasm, cell, 65
- Cytosponge detection method, Barrett's oesophagus, 182–184
- D'Amato, Robert, 166
- Darwin, Charles, 29; see also hyperdynamic Darwinism
- dasatinib, 162
- Deep Blue IBM computer, 100
- Delbrück, Max, 50, 211–214
- DeMars, Robert, 90
- Denmark, breast cancer screening, 150
- 2-deoxyglucose glycolysis inhibitors, 163–164
- diet, role in cancer, 107–108
 - best practice, 108, 116–118, 145
 - calcium, 113
 - dietary fibre, 113–114
 - folate, 112
 - meat, 110–112, 145
 - Nurses' Health Study, 109–110

222 INDEX

- diet, role in cancer (cont.)
 study methodology, **108–109**
 sugar, 114–116
 tea and coffee, 128–129
 vegetables, 110–112
- dietary supplements, 110, 111, 117, 146
- DNA, 49–50
 bases and coding amino acids, 54–55, 82, 82–84
 chromothripsis, 93–95
 developments leading towards sequencing, 56–57, 58–60
 double helix structure, 50–52, 51
 effects of smoking, 132–133
 expression *see* epigenetics
 historical perspectives, 29–34
 sequencing, 60–63, 61, 193–196, 198
 translation, 52–53
 virus impacts, 97–98
see also genetics of cancer; mutations
- dogma of molecular biology, 53
- Doll, Richard, 110, 129–131, 133
- dormant tumours, 6
- driver mutations, 77, 78, 99
 effects of smoking, 132
 machine learning approach to identifying, 100
 in non-cancerous tissue, 195
 replicative mutations, 104
- drug nomenclature, **160**
- drug resistance
 antibiotics, 147–148
 chemotherapy drugs, 147–148, 161, 162
- Dutch famine, 185
- Earth BioGenome Project, 62, 194
- economic development, and cancer, 38, 46–47
- EGFR *see* epidermal growth factor receptor
- Egypt, Ancient, 19–20
- Ehrlich, Paul, 30, 147
- The Eighth Day of Creation* (Judson), 52
- Einstein, Albert, 11
- electromagnetic radiation, 135–136
 Chernobyl power plant accident, 139–140
 Fukushima power plant accident, 140–141
 high-frequency magnetic fields, 143
 Hiroshima and Nagasaki nuclear bombing, 138–139
 ionizing, 135, 136–137
 low-frequency magnetic fields, 142
 radium girls, 137
 radon, 144
 unethical human experiments, 138
 UV radiation, 141–142
- enasidenib, 164
- endocrine therapy, 158–160
- environment, role in cancer, 103, 145;
see also tumour microenvironment
- epidemiology of cancer, 35, 47
 causatory factors, 46–47
 expenditure on research, 42–45
 global data, 35–38, 37
 survival rates, 202
 twentieth century increasing risks of cancer diagnosis, 44–45
 twenty-first-century progress, 45–47
see also individual countries by name
- epidermal growth factor receptor (EGFR)
 DNA mutations, 84–86, 85
 gene amplification, 89
 targets for anti-cancer drugs, 161–162
- epigenetics, 184–185
 Dutch famine, 185
 non-invasive tests, 185–186
 targets for anti-cancer drugs, 164, 165, 186–187
- Epstein–Barr virus, 98

- Escherichia coli*, 13, 122–123
ethics, human radiation experiments, 138
European Prospective Investigation into Cancer and Nutrition (EPIC), 113
European Union, epidemiology of cancer, 40
evolution of cancer cells, 16, 17, 29, 195–197; *see also* genomic instability
evolution of organisms, 29, 65
exosomes, 167–170
- Farber, Sidney, 156–157
fatty acids, cell membranes, 65
FDG-PET (fluorine-18 deoxyglucose positron emission tomography), 154
Ferry, Georgina, 61
fibre, dietary, 113–114
fibroblasts, cancer-associated, 120–121, 173
field asymmetric ion mobility spectroscopy, 182
Firmicutes, 122
FISH (fluorescence *in-situ* hybridization), 87
5-azacitidine (AZA), 186, 187
5-fluorouracil (5-FU), 157
Fleming, Alexander, 147
flexible molecules, 67
fluid mosaic cell membranes, 66
fluorine-18 deoxyglucose positron emission tomography (FDG-PET), 154
folate/folic acid, 112, 156–157
Folkman, Judah, 165
food supplements, 110, 111, 117, 146
Franklin, Rosalind, 50
Fuchs, Ernst, 166
Fukushima power plant accident, 140–141
fulvestrants, 159
fungal microbiome, human, 126–128
Fusobacterium, 123
- Gamma rays, 135
gastro-oesophageal reflux disease (GERD), 182–184
GDP (guanosine diphosphate), 83–84
Gellert, Martin, 58
Gelsinger, Jesse, 177
gemcitabine, 171
gender *see* sex differences
gene amplification, 88–90; *see also* single-nucleotide polymorphisms
gene, definition, 3; *see also* DNA
gene expression *see* epigenetics
gene knock-out, *RB1* gene, 90–92, 91
gene therapy, 165, 177–181, 179
genetics of cancer, 48
atoms and molecules, 49
central dogma of molecular biology, 53
developments towards DNA sequencing, 56–57, 58–60
DNA bases and coding amino acids, 4, 54–55
DNA double helix, 50–52, 51
effects of smoking, 132–133
gene sequencing, 60–63, 61, 193–196, 198
genetic mapping, 57–58
genetic material, 49–50
intergenerational inheritance of breast cancer, 3–4
messenger RNA and translation of DNA code, 52–53
protein synthesis, 52–53
RNA expression, 55–56
see also genomic instability,
genome, 3
genome editing, 178, 179

224 INDEX

- genome sequencing, 60–63, 61, 193–196, 198
- genome-wide association studies (GWAS), 96
- genomic analysis, 101–102
- genomic instability, cancer cells, 16, 76, 77
- biopsy, 153
- causation of cancer, 70–71, 103–104
- common misunderstandings, 203
- evolution of tumour cells, 16, 17, 29, 195–197
- new developments in genomics, 195
- replicative mutations, 104
- see also tumour heterogeneity
- genomics, new developments, 193–195
- Gey, George and Margaret, 15
- Gilbert, Walter, 60, 211–214
- Gilman, Alfred, 155
- glioblastoma multiforme, 164, 190
- glioma, 143
- global data, epidemiology, 35–38, 37
- glucose, metabolism of cancer cells, 33
- glucosinolates, 112
- glutathione, 54
- glycolysis inhibitors/glycolytic pathway, 33, 163–164
- Goldacre, Ben, 117
- Goodman, Louis, 155
- Greaves, Mel, 87
- Greece, Ancient, 20–21
- green tea, 164
- Greene, Howard, 15
- guanosine diphosphate (GDP), 83–84
- gut flora see microbiome
- H101 adenoviruses, 164–165
- Haber, Fritz, 156, 211–214
- haemoglobin, 55
- Haldane, J. B. S., 67
- Hallmarks of Cancer* (Hanahan and Weinberg), 159
- Halsted, William, 27
- Handley, William Sampson, 28
- Hanahan, Doug, 159
- Hansemann, David Paul von, 31
- head and neck cancer, 164–165
- HeLa cells, 15
- Helicobacter pylori*, 134
- hepatitis B virus (HBV), 97, 170
- HER2 see human epidermal growth factor receptor
- herbal treatments for cancer, 23, 164
- herceptin, 89, 162
- herpes virus family, Burkitt's lymphoma, 98
- Hershey, Alfred, 49, 211–214
- hiccups, cell signalling, 69
- high-frequency magnetic fields, mobile phones, 143
- Hill, Austin Bradford, 129–131
- Hippocrates, 20–21
- Hiroshima nuclear bombing, 138–139
- histones, epigenetic modulation, 184–185
- historical perspectives, 19–20
- Ancient China, 22–23
- Ancient Egypt, 19–20
- Ancient Greece, 20–21
- cancer in turtle fossil, 20, 27
- cell biology, 29–34
- chemotherapy, 155–157
- early scientific developments, 23–24, 25
- eighteenth-century developments, 24–26
- first cancer experiment, 78–80
- first oncogene experiment, 80–81
- imaging, 152
- microscopy, 24, 30, 64
- surgical advances, 26–29

- HIV (human immunodeficiency virus), 11, 98
- Honjo, Tasuku, 175, 211–214
- Hooke, Robert, 24, 25, 64
- Hopkins, Frederick Gowland, 22, 211–214
- hormonal status
breast cancer, 5
historical perspectives, 28
- hormone therapy, 109–110, 158–160
- Hoshino, Ayuko, 169
- Hounsfield, Godfrey, 137, 211–214
- HPV (human papillomavirus), 11–12, 97, 170
- Huggins, Charles Brenton, 28, 79, 155, 211–214
- Human Development Index (HDI), 38
- human epidermal growth factor receptor (HER2), 5, 89, 162
- Human Genome Project, 56, 60–61
- human immunodeficiency virus (HIV), 11, 98
- human papillomavirus (HPV), 11–12, 97, 170
- human T cell lymphotropic virus (HTLV), 98
- Hungerford, David, 86
- Hunter, John, 26
- hydrogen bonds, DNA, 50
- hyper-dynamic Darwinism, 16, 29; *see also* evolution of cancer cells
- IDH (isocitrate dehydrogenase), 164
- IGFII* gene, 185
- imaging, cancer diagnosis/staging/grading, 151–154, 152
- imatinib, 162
- immune response boosters, vaccines, 171
- immune system, role in cancer, 134, 172–173
- immunoglobulin, 162, **163**
- immunology, historical perspectives, 22–23
- immunomodulators, 166, 174–175
- immunotherapy, 173, 174–175
checkpoint inhibitors, 175–177, 176
nanotechnology, 189
new developments, 197
see also gene therapy
- in-vitro* studies, 14–15
- individual variation, DNA mutations, 96;
see also personalized/precision medicine
- infection, cancers arising from, 11–12, 134–135
common misunderstandings, 202–203
targets for anti-cancer drugs, 159
- inflammation, 134–135
- inherited mutations, 3–4, 145; *see also* epigenetics
- instability, DNA *see* genomic instability
- insulin, 59, 66
- Internet, use in self-diagnosis of cancer, 1
- interspecific differences in cancer incidence, 76–77
- iodine, radioactivity in, 139–140
- ionizing radiation, 135, 136–137
medical uses, 136–137, 152–153
radon, 144
- isocitrate dehydrogenase (IDH), 164
- Jacks, Tyler, 125
- Jacob, François, 52, 211–214
- Johannsen, Wilhelm, 3
- Jolie, Angelina, 4–5
- Judson, Horace, 52
- Kaposi's sarcoma, 98
- Keren, Leeat, 197
- kinases
cell signalling, 67, 71

226 INDEX

- kinases (cont.)
 targets for anti-cancer drugs, 159,
 160–161
see also MAPK signalling pathway
- Kishony, Roy, 147
- knock-out, genes, 90–92, 91
- Knudson, Alfred, 91
- Koch, Robert, 30
- Kornberg, Arthur, 58, 211–214
- KRAS gene, 192–193
- Krebs cycle, 33
- Lacks, Henrietta, 15
- Laënnec, René-Théophile-Hyacinthe, 26
- Lane, David, 74
- Larotrectinib, 171
- Leber's congenital amaurosis,
 BRILLIANCE trial, 180
- Leeuwenhoek, Antonie van, 64
- LEP gene, 119–120
- leptin, 120–121
- leukaemias, 10
 chromosome translocation, 86
 DNA mutations, 86–88
 low-frequency magnetic fields, 142
 role of folic acid, 156–157
 targets for anti-cancer drugs, 162
- Lickint, Fritz, 131
- life expectancy, 38, 45; *see also* ageing
- lifestyle factors, 47; *see also* causatory
 factors
- Lindskog, Gustaf, 155
- linkage maps, 57–58
- liquid biopsy, 181–182
- liver cancer
 epidemiology, 36
 hepatitis B virus, 97
 nanotechnology, 189
- low-frequency electromagnetic
 fields, 142
- lung cancer
 epidemiology, 36, 39–40, 45
 metastasis, 169–170
 replicative mutations, 104
 role of microbiome, 124–125
 screening, 149
 smoking, 129–131, 130
 tuberculosis bacterium, 134–135
- Luria, Salvador, 50, 90, 211–214
- Lyden, David, 167, 169
- lymphocytes, 177
- lymphomas, 10–11, 162
- machine learning approach, 99–101,
 198
- magnetic resonance imaging (MRI),
 151–154
- Malassezia* spp. 127
- malignant vs. benign tumours, 6–8
- mammography, 149–151
- mannose binding lectin (MBL), 127
- MAPK signalling pathway
 DNA mutations causing faulty
 proteins, 85
 personalized medicine, 192
 targets for anti-cancer drugs, 161
- mathematical modelling, 198
- Matthaei, Heinrich, 53
- MC29 virus, role in initiation of
 cancer, 80
- meat, best practice to avoid cancer,
 111–112, 145
- meganucleases, gene therapy, 178
- melanoma
 targets for anti-cancer drugs, 160–161,
 164–165
 UV radiation, 141–142
- melatonin, 144
- membranes, cell, 65–66
- Meselson, Matthew, 52
- mesothelioma, 133
- messenger RNA, 52–53

- metabolic biomarkers, 149, 154, 168–169
- metabolic effects, obesity, 118–119, 120–121
- metabolic targets, anti-cancer drugs, 159, 163–164
- metabolism of body, replicative mutations, 104
- metabolism of cancer cells, 33
- metabolomics, 107–108
- metastasis, 2, 12, 201
 - gene amplification/mutational load, 89
 - role of microbiome, 123
 - seed and soil theory, 166–167, 172
 - targets for anti-cancer drugs, 159, 166–170
- metformin, 163–164
- methotrexate, 156–157, 161
- methylscape/methylation landscape, 185–186; *see also* epigenetics
- methyltransferase enzymes, 184–185
- Michelet, Xavier, 121
- micro RNAs, 95–96
- microbiome, human, 114, 121–122
 - antibiotics use, 123–124
 - circadian rhythm, 125–126
 - fungal, 126–128
 - lung cancer, 124–125
 - role in cancer, 122–123, 124–125
- microenvironments *see* tumour microenvironments
- Micrographia* (Hooke), 24, 64
- microscopy, historical perspectives, 24, 30, 64
- Miescher, Friedrich, 30
- mitochondria, 3, 65
- mitochondrial inhibitors, 163–164
- mobile phones, high-frequency magnetic fields, 143
- Mohs, Frederic E., 29
- molecules, 49
- moles, 8–9
- Mongolia, epidemiology of cancer, 36–38
- monoclonal antibodies, 162, **163**
- Morgan, Hunt, 31
- mortality rates from cancer
 - UK, 39, 40
 - worldwide, 36–38, 37
- MRI (magnetic resonance imaging), 151–154
- Mullis, Kary, 59, 211–214
- multi cellular organisms, evolution, 65
- multiple myeloma, 166
- mustard gas, 156
- mutations, DNA, 3–6, 16, 76–78, 78
 - breast cancer mutational signatures, 196–197
 - cancer cells as mosaics, 195–196
 - chromosome translocation, 86
 - chromothripsis, 93–95, 99
 - effect on protein synthesis, 82, 82–84, 83
 - effect on cell signalling/communication, 82–84, 84
 - effect on gene regulation, 88
 - effect on protein synthesis, 82, 82–84, 83
 - epidermal growth factor receptor, 84–86, 85
 - gene amplification, 88–90
 - gene knock-out, 90–92, 91
 - genetic basis to cancer classification, 101–102
 - hereditary and environmental causes, 103
 - historical perspectives, 78–80
 - individual variation and SNPs, 96
 - inherited mutations, 3–4, 145
 - leukaemia, 86–88
 - machine learning approach, 99–101

228 INDEX

- mutations, DNA (cont.)
 micro RNAs, 95–96
 in non-cancerous tissue, 195
 oncogenes, 80–81
 p53 transcription factor, 92–93
 Pan-Cancer Atlas, 98–99, 101
 protein synthesis, 81
 RAS gene example, 82–84, 83
 replicative mutations, 104
 TP53 gene, 92–93
 viruses, role in, 79, 97–98
 whole-genome doubling, 89–90
 see also DNA; genetics; genomic instability
MYC gene, 80
 Burkitt's lymphoma, 88
 gene amplification, 88–89
 personalized medicine, 193, 194
Mycobacterium tuberculosis, lung cancer, 134–135
 mycobiome, 126–128

 Nagasaki nuclear bombing, 138–139
 nanotechnology/nanobots, 187–189, 188
 natural killer (NK) cells, 121
 Needham, Joseph, 22
 neoadjuvant chemotherapy, 155
 Nicholson, Jeremy, 114
 nickases, gene therapy, 178, 180
 Nirenberg, Marshall, 53, 211–214
 nitrogen mustards, 155–156
 Nobel Prize winners, 211–214
 non-invasive tests, epigenetics, 185–186;
 see also cytosponge detection method; liquid biopsy
 non-small cell lung cancer (NSCLC), 89
 Nowell, Peter, 86
 nucleases, gene therapy, 178, 180
 nucleus, cell, 65

 Nurse, Paul, 211–214
 Nurses' Health Study, role of diet in cancer, 109–110

 obesity, 118–119
 antibiotics use, 123–124
 causes of, 119–120
 metabolic effects, 118–119, 120–121
 role in cancer, 46, 109–110, 116, 145;
 see also diet
 oestrogen receptor antagonists, 159
 O'Keefe, Stephen, 113
 olaparib, 192
 omega-3 fatty acids, 65
On the Origin of Species (Darwin), 29
 oncogene addiction, definition, 193
 oncogenes, 74, 80–81
 first oncogene experiment, 80–81
 MYC gene, 80
 RAS gene, 81
 SRC gene, 79–80; see also viruses, oncogenic
 oncoproteins, 159, 160–162
 100,000 Genomes Project, 195
 ONYX-015 adenovirus, 164–165
 open access, human genome, 61–62
 oral contraceptives, role in cancer, 109–110
 ovarian cancer biomarkers, 149
 oxygen radicals, 135, 163–164; see also antioxidants
 oxytocin, 54

 p53 transcription factor, 93
 cell signalling, 73–74
 micro RNAs, 95
 see also *TP53* gene
 paclitaxel, 171
 Paget, Stephen, 166–167
 palbociclib, 157

- palliative chemotherapy, 155
- Pan-Cancer Atlas/Analysis of Whole Genomes, 62, 98–99, 101, 195, 199
- pancreatic cancer, metastasis, 169–170
- pancreatic ductal adenocarcinoma (PDA), 126–128
- Pap test, 149
- Papicolaou, George, 148
- paradox of cancer, 2
- PARP (poly (ADP-ribose) polymerase 1) inhibitors
drug nomenclature, **160**
synthetic lethality, 190–192, 191
- passenger mutations, 77
- passive smoking, 131–132
- Pasteur, Louis, 30
- PCR (polymerase chain reaction), 59
- PDA (pancreatic ductal adenocarcinoma), 126–128
- PD-1 protein, 175–177, 176, 180–181
- PDCD1* gene, 180–181
- PD-L1 protein, tumour microenvironment, 197
- PEG (poly-ethylene glycol), nanotechnology, 189
- pembrolizumab, 171
personalized medicine, 192–193, 194, 199
- Perutz, Max, 55, 211–214
- PET (positron emission tomography), 151–154
- Peto, Richard, 110, 133
- Philadelphia chromosome, 86
- phospholipids, cell membranes, 65
- phosphorylation, cell signalling, 67, 71, 73
- physical exercise, role in cancer, 109–110
- phytochemicals, 23
- plant cancers, 13–14
- plasma membrane, cell, 65–66
- plasmids, 59
- poly-ethylene glycol (PEG), nanotechnology, 189
- polymerase chain reaction (PCR), 59
- Pope, Alexander, 1, 11
- positron emission tomography (PET), 151–154
- postmenopausal hormone therapy, 109–110
- potassium, radioactivity in, 136
- Pott, Percival, 25–26
- precision medicine, 192–193, 194, 199
- processed meat, 46, 108, 111–112, 117–118
- prospective studies, role of diet in cancer, **109**
- prostate cancer
biomarker, 149
epidemiology, 36, 39–40
metastasis, 169–170
replicative mutations, 104
- prostate specific antigen (PSA)
biomarker, 149
- proteasome inhibitors, drug nomenclature, **160**
- proteins, 4, 52–53, 54–55
chromosome translocation causing faulty, 86
DNA bases and coding amino acids, 54–55
effect of single base changes on synthesis, 82–84
folding and shape, 55, 93
mutations causing faulty, 81
switch proteins, 168
- proto-oncogenes, 74
- PSA (prostate specific antigen)
biomarker, 149

230 INDEX

- pseudoscience, role of diet, 117
- public health advice, best practice to avoid cancer, 146
- Qasim, Waseem, 178
- quercetin, 164
- radiation *see* electromagnetic radiation
- Radiation Effects Research Foundation, 138
- radiotherapy, 137, 152–153, 190
- radium girls, 137
- radon, 144
- raloxifene, 158
- Ramakrishnan, Venkatraman, 52, 211–214
- Ramazzeni, Bernardino, 24–25
- randomized controlled trials (RCTs), role of diet in cancer, **109**
- RAS gene, 81
- effect of mutations, 82–84, 83
- personalized medicine, 192, 194
- RB 1 gene,
- cell signalling, 73, 73
- gene knock-out, 90–92, 91
- RCTs *see* randomized controlled trials
- reactive oxygen species (ROS), 135, 163–164; *see also* antioxidants
- receptor tyrosine kinases (RTKs), 67, 68
- recombinant proteins, 59
- red meat, best practice to avoid cancer, 111–112, 145
- replication mutations, 104, 105, 145
- research funding, cancer, 42–45
- restriction sites/restriction enzymes, 58
- retinoblastoma, 91, 91; *see also* RB1 gene
- retrospective studies, role of diet in cancer, **108**
- retroviruses, 59, 79, 98
- reverse transcriptase (RT), 59
- REVOLVER (repeated evolution in cancer), 100–101
- ribosomes, 52
- risk factors for cancer, common misunderstandings, 202; *see also* causatory factors
- rituxamib, 162
- RNA
- expression, 55–56
- translation of DNA code, 52–53
- RNA polymerase, 53
- RNA viruses (retroviruses), 59, 79, 98
- robots, nanotechnology, 187–189, 188
- ROS *see* reactive oxygen species
- Rosenberg, Steven, 177
- roundworm (*Caenorhabditis elegans*), 56–57
- Rous, Peyton, 78–80, 211–214
- Roux, Wilhelm, 14
- Rowley, Janet, 86
- Royal Society of London, historical perspectives, 23–24
- RT (reverse transcriptase), 59
- RTKs (receptor tyrosine kinases), 67, 68
- saccharin, 128
- salt consumption, 146
- Samuel, Arthur, 100
- Sanger, Fred, 54, 60, 211–214
- Sanger Institute, 60–61
- sarcomas, 10
- Sattely, Elizabeth, 111
- Saudi Arabia, epidemiology of cancer, 36–38
- Schoenfeld, Robert, 49
- Science and Civilisation in China* (Needham), 22, 23
- screening for cancer, 148–151
- scrotal cancer, chimney sweeps, 25–26
- second-hand smoke (passive smoking), 131–132

- seed and soil theory of metastasis,
166–167, 172
- selective oestrogen receptor degraders
(SERDs), 159
- selective oestrogen receptor modulators
(SERMs), 158–160
- self-diagnosis of cancer, 1
- sex differences
 alcohol use, 106
 dietary fibre, 113
 incidence of cancer, 11
- Sharpless, Barry, 189
- Shubin, Neil, 69
- Sievert, Rolf, 137
- signalling *see* cell signalling
- single-nucleotide polymorphisms
(SNPs), 96
- Sipuleucel-T vaccines, 171
- skin cancer, 29
- smallpox, 22–23
- Smith, Edwin, 19–20
- smoking, 46, 129
 effect on genome, 132–133
 lung cancer, 129–131, 130
 passive, 131–132
 protein folding and shape, 93
 role in cancer, 45, 46–47, 109–110,
 129–132
- SNPs (single-nucleotide
 polymorphisms), 96
- somatic mutation, definition, 78
- sorafenib, 189
- Sottoriva, Andrea, 100
- species differences in cancer incidence,
76–77
- SpiderMass system, 155
- SRC* gene, 79–80
- Stephens, Philip, 94
- steroid hormones, 69–70, 158–160
- Stevens, Albert, 138
- Stewart Report, 143
- stomach cancer, 36, 134
- Stratton, Michael, 160
- stress, role in cancer, 144–145
- strontium, radioactivity in, 139–140
- Subbarow, Yellapragada, 156
- sugar, role in cancer, 114–116, 128
- Sulston, John, 57–58, 60–62, 211–214
- SUMMIT study, lung cancer, 149
- suppression immunotherapies, 174–175
- surgery, historical perspectives, 24–25
- survival rates, 202; *see also* epidemiology
 of cancer
- Sutton, Walter Stanborough, 32
- switch proteins, 168
- Switzerland, breast cancer screening, 150
- synthetic lethality, 190–192, 191
- T-cells
 CAR-T cell therapy, 177–178
 checkpoint inhibitors, 175–177, 176
- TALENs (transcription activator-like
 effectors), 179
- talimogene laherparepvec (T-VEC),
164–165, 171
- tamoxifen, 158, 161
- Taubes, Gary, 117
- TB (tuberculosis), lung cancer, 134–135
- tea, role in cancer, 128–129
- TEL* gene, 87
- telomeres, 99
- Temin, Howard, 59, 211–214
- thalidomide, 166
- theoretical models, 15–16
- theranostics, nanotechnology, 187
- Thiersch, Karl, 30
- third-generation sequencing, 62
- 3D printing, 190
- thyroid cancer, 140
- tissue-agnostic drugs, 159, 171
- TNBCs (triple-negative breast cancers), 5
- tobacco *see* smoking

232 INDEX

- Todaro, George, 15
 Tomasetti, Christian, 104
 toremifene, 158
 tortoiseshell cats, gene expression, 184
 TP53 gene, 200
 breast cancer screening, 151
 DNA mutations, 92–93
 effects of smoking, 132–133
 gene therapy, 180
 targets for anti-cancer drugs, 164–165;
 see also p53 transcription factor
 TRACERx (Tracking Cancer Evolution
 through Therapy) project, 90
 transcription activator-like effectors, gene
 therapy, 178
 transcription factors, 56, 70, 73, 85
 transfer learning, 99–101, 198
 transformation (normal cells becoming
 cancerous), 79
 translation, DNA code, 52–53
 Trau, Matt, 186
 treating cancer, 14, 174, 197–199
 breath biopsy, 182
 common misunderstandings, 203
 Cytosponge detection method, 182–184
 epigenetic drugs, 186–187
 liquid biopsy, 181–182
 new developments in genomics,
 193–195
 personalized medicine, 192–193, 194
 synthetic lethality, 190–192, 191
 tumour-on-a-chip/3D printing, 190;
 see also chemotherapy;
 immunotherapy; nanotechnology;
 radiotherapy
 triple-negative breast cancers (TNBCs), 5
 tropomyosin kinase receptors, 171
 tuberculosis (TB), lung cancer, 134–135
 tumour biomarkers, 149, 154, 168–169
 tumour heterogeneity, 87–88; *see also*
 genomic instability
 tumour microenvironments
 breast cancer, 197
 checkpoint blockade, 175–177
 common misunderstandings, 203
 targets for anti-cancer drugs, 159,
 172, 172
 tumour-on-a-chip/3D printing, 190
 tumour suppressor genes, 75, 91, 93
 tumour-on-a-chip, 190
 tumour-agnostic drugs, 159, 171
 turmeric, 164
 turtles, cancer in, 20, 21
 2-deoxyglucose glycolysis inhibitors,
 163–164
 two-hit model, 91
 tyrosine kinase inhibitors
 drug nomenclature, **160**
 targets for anti-cancer drugs, 161–162,
 171; *see also* receptor tyrosine
 kinases
 ultrasound, 151–154
 United Kingdom, epidemiology of
 cancer, 36–38, 39–41, 40, 42
 United States Preventative Services Task
 Force, 150
 United States, epidemiology of cancer,
 36–38, 41–42
 black–white gap in cancer survival, 42,
 45–46
 causation, 42
 expenditure on research, 42–45
 incidence and mortality rates by state,
 41, 42, 43
 incidence and mortality rates by type
 of cancer, 41–42
 UV (ultraviolet) radiation, 141–142
 vaccines
 immune response boosters, 171
 oncogenic viruses, 170, 175

- Varmus, Harold, 80, 211–214
- vascular endothelial growth factor (VEGF), 165–166
- vegetables, role of diet in cancer, 110–112
- vemurafenib, 161, 176, 192
- vestibular schwannoma, 143
- Virchow, Rudolph, 30
- virotherapy, 177–178
- viruses, oncogenic, 111, 170
- DNA mutations, 79, 97–98
 - MC29 virus, 80
 - targets for anti-cancer drugs, 159, 170
 - vaccines, 170, 175
- vitamin D, 141–142
- vitamin and mineral supplements, 110, 111, 117, 146
- Vogelstein, Bert, 104
- Warburg, Otto, 33, 211–214
- Warburg effect, 163–164
- warts, 8–9; *see also* human papillomavirus
- Waterston, Robert, 57–58
- Watson, James, 50, 51, 53, 211–214
- Weinberg, Robert, 81, 159
- Western diets, 108, 113–114; *see also* diet
- whole-genome doubling (WGD), 89–90
- wildlife, effects of radioactivity, 140
- Wilkins, Maurice, 50, 211–214
- World Cancer Research Fund, 111, 145
- xeroderma pigmentosum (XP), 94
- X-rays, 135, 136–137
- Yan, Hao, 189
- Your Inner Fish* (Shubin), 69
- zinc chloride, 28–29
- zinc finger nucleases, gene therapy, 178